Rakovina Therapeutics: Funding, Investors & Team (Sep 2026)
Rakovina Therapeutics specializes in creating innovative cancer treatments using new technology that targets DNA damage response. The company has created a series of inhibitors that aim to advance potential drug candidates for human clinical trials and approval from regulatory agencies like Health Canada and the FDA for new cancer therapies.
Rakovina Therapeutics has raised $6.0M across 4 funding rounds on record, the most recent an undisclosed round of $2.1M announced in May 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rakovina Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2025.
Rakovina Therapeutics Funding Rounds
Rakovina Therapeutics raised $1.5M in an undisclosed round announced in May 2023.
1 years later, an undisclosed round of $1.5M was announced in May 2024.
6 months later, an undisclosed round of $890k was announced in Nov 2024.
6 months later, an undisclosed round of $2.1M was announced in May 2025.
Rakovina Therapeutics Founders and Leadership Team
Contact details for the Rakovina Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Rakovina Therapeutics Funding Compared to Other Biotechnology Startups
Rakovina Therapeutics' latest round of $2.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rakovina Therapeutics in Biotechnology and Vancouver
Companies Similar to Rakovina Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Rakovina Therapeutics Funding FAQs
What does Rakovina Therapeutics do?
Rakovina Therapeutics specializes in creating innovative cancer treatments using new technology that targets DNA damage response. The company has created a series of inhibitors that aim to advance potential drug candidates for human clinical trials and approval from regulatory agencies like Health Canada and the FDA for new cancer therapies.
How much funding has Rakovina Therapeutics raised?
Rakovina Therapeutics has raised $6.0M across 4 rounds on record. The most recent is an undisclosed round of $2.1M announced in May 2025.
When did Rakovina Therapeutics last raise funding?
Rakovina Therapeutics' most recent funding round on record is an undisclosed round of $2.1M, announced in May 2025.
Who founded Rakovina Therapeutics?
FundedIQ lists Jeffrey Bacha (Founder), Mads Daugaard (Founder) at Rakovina Therapeutics.
Where is Rakovina Therapeutics headquartered?
Rakovina Therapeutics is based in Vancouver, British Columbia, Canada.
How many employees does Rakovina Therapeutics have?
Rakovina Therapeutics is in the 1-10 employee band.
How does Rakovina Therapeutics' funding compare to other Biotechnology startups?
Rakovina Therapeutics' latest round of $2.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Rakovina Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rakovina Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.